Protective effects of the neuropeptide PACAP in diabetic retinopathy

Cell and Tissue Research

Volumn 348, Issue 1, 2012, Pages 37-46

  Szabadfi, Krisztina ^a   Atlasz, Tamas ^a   Kiss, Peter ^a   Reglodi, Dora ^a   Szabo, Aliz ^b   Kovacs, Krisztina ^b   Szalontai, Balint ^a   Setalo Jr , Gyorgy ^b   Banki, Eszter ^a   Csanaky, Katalin ^a   Tamas, Andrea ^a   Gabriel, Robert ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Diabetic retinopathy; Neuroprotection; PAC1 R; PACAP; Rat (adult male Wistar); Retina

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PAC1 RECEPTOR; RECEPTOR PROTEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL LOSS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG MECHANISM; EYE PROTECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MUELLER CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RETINA AMACRINE CELL; RETINA CONE; RETINA GANGLION CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOTTING, WESTERN; DIABETIC RETINOPATHY; DOPAMINERGIC NEURONS; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; MALE; NEUROGLIA; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTECTIVE AGENTS; RATS; RATS, WISTAR; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RETINA; RETINAL CONE PHOTORECEPTOR CELLS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; RATTUS;

EID: 84859444917     PISSN: 0302766X     EISSN: 14320878     Source Type: Journal    
DOI: 10.1007/s00441-012-1349-0     Document Type: Article

References (40)

1. Alvarez Y, Chen K, Reynolds AL,Waghorne N, O'Connor JJ, Kennedy BN (2010) Predominant cone photoreceptor dysfunction in a hyperglycaemic model of non-proliferative diabetic retinopathy. Dis Model Mech 3:236-245
2. Atlasz T, Szabadfi K, Kiss P, Racz B, Gallyas F, Tamas A, Gaal V, Marton Z, Gabriel R, Reglodi D (2010) Review of pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects. Ann N Y Acad Sci 1200:128-139
3. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783-791 (Pubitemid 28399611)
4. Brandies R, Yehuda S (2008) The possible role of retinal dopaminergic system in visual performance. Neurosci Biobehav Rev 32:611-656 (Pubitemid 351329405)
5. Brecha NC, Oyster CW, Takahashi ES (1984) Identification and characterization of tyrosine hydroxylase immunoreactive amacrine cells. Invest Ophthalmol Vis Sci 25:66-70 (Pubitemid 14220989)
6. Cameron MA, Pozdeyev N, Vugler AA, Cooper H, Iuvone PM, Lucas RJ (2009) Light regulation of retinal dopamine that is independent of melanopsin phototransduction. Eur J Neurosci 29:761-767
7. Castorina A, Giunta S, Mazzone V, Cardile V, D'Agata V (2010) Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells. Peptides 31:2276-2283
8. Dickinson T, Mitchell R, Robberecht P, Fleetwood-Walker SM (1999) The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. Neuropharmacology 38:167-180 (Pubitemid 29073536)
9. Engerman RL, Kern TS (1995) Retinopathy in animal models of diabetes. Diabetes Metab Rev 11:109-120
10. Fernstrom MH, Volk EA, Fernstrom JD, Iuvone PM (1986) Effect of tyrosine administration on dopa accumulation in light- and dark-adapted retinas from normal and diabetic rats. Life Sci 39:2049-2057 (Pubitemid 17194957)
11. Fong DS, Aiello LP, Ferris FL 3rd, Klein R (2004) Diabetic retinopathy. Diabetes Care 27:2540-2553 (Pubitemid 39281419)
12. Gastinger MJ, Singh RS, Barber AJ (2006) Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 47:3143-3150 (Pubitemid 351639794)
13. Gastinger MJ, Kunselman AR, Conboy EE, Bronson SK, Barber AJ (2008) Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest Ophthalmol Vis Sci 49:2635-2642
14. Gustincich S, Feigenspan A, Wu DK, Koopman LJ, Raviola E (1997) Control of dopamine release in the retina: a transgenic approach to neural networks. Neuron 18:723-736 (Pubitemid 27232784)
15. Holopigian K, Greenstein VC, Seiple W, Hood DC, Carr RE (1997) Evidence for photoreceptor changes in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 38:2355-2365 (Pubitemid 27446953)
16. Jeon CJ, Strettoi E, Masland RH (1998) The major cell populations of the mouse retina. J Neurosci 18:8936-8946 (Pubitemid 28491758)
17. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF (2004) The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122:552-563 (Pubitemid 38456292)
18. Kurtenbach A, Mayser HM, Jägle H, Fritsche A, Zrenner E (2006) Hyperoxia, hyperglycemia, and photoreceptor sensitivity in normal and diabetic subjects. Vis Neurosci 23:651-661 (Pubitemid 46024755)
19. Li M, Maderdrut JL, Lertora JJ, Arimura A, Batuman V (2008) Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases. Regul Pept 145:24-32 (Pubitemid 350296365)
20. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, TanaseD, Strother JM (1998) Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes 47:815-820 (Pubitemid 28201813)
21. Liu X, Mameza MG, Lee YS, Eseonu CI, Yu CR, Kang Derwent JJ, Egwuagu CE (2008) Suppressors of cytokine-signaling proteins induce insulin resistance in the retina and promote survival of retinal cells. Diabetes 57:1651-1658
22. MacNeil MA, Masland RH (1998) Extreme diversity among amacrine cells: implications for function. Neuron 20:971-982 (Pubitemid 28247402)
23. Mohamed Q, Gillies MC, Wong TY (2007) Management of diabetic retinopathy. A systematic review. JAMA 298:902-916
24. Nishimura C, Kuriyama K (1985) Alterations in the retinal dopaminergic neuronal system in rats with streptozotocin-induced diabetes. J Neurochem 45:448-455 (Pubitemid 15233944)
25. Northington FK, Hamill RW, Banerjee SP (1985) Dopamine-stimulated adenylate cyclase and tyrosine hydroxylase in diabetic rat retina. Brain Res 337:151-154 (Pubitemid 15008296)
26. Park JW, Park SJ, Park SH, Kim KY, Chung JW, Chun MH, Oh SJ (2006) Up-regulated expression of neuronal nitric oxide synthase in experimental diabetic retina. Neurobiol Dis 21:43-49
27. Park SH, Park JW, Park SJ, Kim KY, Chung JW, Chun MH, Oh SJ (2003) Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 46:1260-1268
28. Phipps JA, Fletcher EL, Vingrys AJ (2004) Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest Ophthalmol Vis Sci 45:4592-4600 (Pubitemid 39564688)
29. Portha B, Levacher C, Picon L, Rosselin G (1974) Diabetogenic effect of streptozotocin in the rat during the perinatal period. Diabetes 23:889-895
30. Racz B, Gallyas F Jr, Kiss P, Toth G, Hegyi O, Gasz B, Borsiczky B, Ferencz A, Roth E, Tamas A, Lengvari I, Lubics A, Reglodi D (2006) The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involve inhibition of proapoptotic signaling pathways. Regul Pept 137:20-26 (Pubitemid 44781242)
31. Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, Abe H, Takei N (2004) Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53:2412-2419 (Pubitemid 39145597)
32. Shen X, Zhong Y, Xie B, Cheng Y, Jiao Q (2010) Pigment epithelium derived factor as an anti-inflammatory factor against decrease of glutamine synthetase expression in retinal Müller cells under high glucose conditions. Graefes Arch Clin Exp Ophthalmol 248: 1127-1136
33. Shirao Y, Kawasaki K (1998) Electrical responses from diabetic retina. Prog Retin Eye Res 17:59-76 (Pubitemid 28040753)
34. Steinle JJ (2010) Topical administration of adrenergic receptor pharmaceutics and nerve growth factor. Clin Ophthalmol 4:605-610
35. Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50:537-546
36. Tamas A, Gabriel R, Racz B, Denes V, Kiss P, Lubics A, Lengvari I, Reglodi D (2004) Effects of pituitary adenylate cyclase activating polypeptide in retinal degeneration induced by monosodium-glutamate. Neurosci Lett 372:110-113 (Pubitemid 39505238)
37. Tao W (2006) Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 6:717-726
38. Witkovsky P, Schutte M (1991) The organization of dopaminergic neurons in vertebrate retinas. Vis Neurosci 7:113-124
39. Yamamoto K, Hashimoto H, Tomimoto S, Shintani N, Miyazaki J, Tashiro F, Aihara H, Nammo T, Li M, Yamagata K, Miyagawa J, Matsuzawa Y, Kawabata Y, Fukuyama Y, Koga K, Mori W, Tanaka K, Matsuda T, Baba A (2003) Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 52:1155-1162 (Pubitemid 36523350)
40. Zeng XX, Ng YK, Ling EA (2000) Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 17:463-471